Evidence map›Paper›PMID 41153078›Full record

ArticleCNS neuroscience & therapeutics2025

Hengri Cong, Leilei Yuan, Pei Zheng, Xuan Xu, Wenyue Dong, DeCai Tian, Linlin Yin, Yueta Ma, Tian Song, Yanxue Zhao and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. CNS neuroscience & therapeutics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hengri CongDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Leilei YuanDepartment of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-8222-9436
Pei ZhengDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuan XuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0009-0004-0910-4006
Wenyue DongSchool of Basic Medical Sciences Peking University, Beijing, China.
DeCai TianDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-5153-2491
Linlin YinChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yueta MaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Tian SongDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yanxue ZhaoChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yun XuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Mengting ZhangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Baitao LiuPeking University Aerospace School of Clinical Medicine, Beijing, China.
Guoqiang ChangDepartment of Neurology, Tianjin Medical University General Hospital, Tianjin, China.ORCID 0000-0003-0308-971X
Ke SunFunctional Neurosurgery Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Wenping MaDepartment of Neurosurgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Lin AiDepartment of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wangshu XuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-4746-2064

Funding

Natural Science Foundation of Beijing Municipality 7222018Natural Science Foundation of Beijing Municipality 7232044
6 · The paper itself

Abstract

purposeAnti-AMPAR encephalitis is a rare antibody-mediated disorder, and its clinicoradiological profile is incompletely defined. We aimed to characterize the clinical presentation and cerebral metabolic patterns of Chinese adults with anti-AMPAR encephalitis using

methodsFrom August 2016 to August 2022, we retrospectively identified patients from two neurology centers who were positive for anti-AMPAR antibodies in serum and/or cerebrospinal fluid. Demographic data, presenting symptoms, MRI and

resultsEight patients (four women) were included; median age was 53 years (range 37-63). Anti-AMPA2R antibodies were detected in seven cases and anti-AMPA1R antibodies in one. Limbic manifestations dominated, particularly cognitive decline and abnormal behavior; severe disease necessitated intensive care support in one patient, who nonetheless achieved a good outcome. Malignancy was documented in three individuals (lung carcinoma, hepatocellular carcinoma, and thymoma), and three harbored additional neural autoantibodies. MRI was abnormal in five patients (62.5%). All five subjects who underwent

conclusionAnti-AMPAR encephalitis usually presents as limbic encephalitis and is marked by prefrontal and posterior cingulate hypometabolism on

Indexed as

EncephalitisGyrus CinguliPositron Emission Tomography Computed TomographyPrefrontal CortexAdultAutoantibodiesCohort StudiesFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesAutoantibodiesFluorodeoxyglucose F18Radiopharmaceuticals18F‐FDG PET/CTanti‐AMPAR encephalitiscerebral functionmetabolic patterns

Identifiers

PMID41153078
PMCPMC12568521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.